Clinical Trial VICCBREP12116


An Open-Label, Phase I Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Principal Investigator(s)

Ingrid Mayer


  • Protocol No. VICCBREP12116
  • Open Date: 03/25/2013
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: To determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) and assess the safety of ARN-810 in postmenopausal women with locally advanced or metastatic ER+ (HER2-) breast cancer
  • Disease Sites: Breast
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: ARN-810
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: 01823835
  • Secondary Protocol No: ARN-810-001